Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

336
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
336
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

204
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
204
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

244
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
244
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

309
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
309
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

307
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
307

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of new overlapping and disease-specific genetic risk factors for rheumatoid arthritis and radiographic axial spondyloarthritis: a meta-analysis of three large European populations and functional characterization.

Frontiers in immunology·2026
Same author

The Patient Experience of Cancer-Related Cachexia: Implications for Patient-Reported Outcomes Measures.

Clinical Medicine Insights. Oncology·2026
Same author

Coding systems and monitoring practices across the ERN ReCONNET: insights from a comprehensive survey and unmet needs.

Orphanet journal of rare diseases·2026
Same author

The effects of ischemic preconditioning and placebo maneuvers are similar during arm-cranking performance in upper-body trained athletes.

European journal of applied physiology·2026
Same author

Comment on: Cancer-associated myositis before and after the COVID-19 pandemic onset.

Clinical and experimental rheumatology·2026
Same author

Systemic Sclerosis Associated Pulmonary Arterial Hypertension with Venous Involvement - a Novel ABCC8 Pathogenic Variant.

Arquivos brasileiros de cardiologia·2026

Related Experiment Video

Updated: Mar 13, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K

Differentiating biosimilarity and comparability in biotherapeutics.

Valderilio Azevedo1, Brian Hassett2, João Eurico Fonseca3

  • 1Federal University of Paraná, Curitiba, PR, Brazil.

Clinical Rheumatology
|October 14, 2016
PubMed
Summary

Manufacturing changes to originator biologics require comparability assessments to ensure quality, safety, and efficacy. This differs from biosimilarity assessments, which evaluate a new biologic

Keywords:
BiosimilarBiosimilarityBiotherapeuticsComparability

More Related Videos

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.5K
Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.7K

Related Experiment Videos

Last Updated: Mar 13, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.3K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.5K
Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research
04:50

Author Spotlight: Biological Standardization to Ensure Reproducibility and Harmonization in Research

Published on: August 4, 2023

1.7K

Area of Science:

  • Biopharmaceutical Manufacturing
  • Regulatory Science
  • Drug Development

Background:

  • Biologic manufacturing involves complex, multi-step processes.
  • Planned manufacturing changes in licensed biologics necessitate regulatory oversight.
  • Comparability assessments ensure post-change product quality, safety, and efficacy.

Purpose of the Study:

  • To clarify the distinction between comparability assessments for originator biologics and biosimilarity evaluations.
  • To examine the regulatory rationale for these distinct approval pathways.
  • To highlight the global application of comparability principles in biosimilar guidelines.

Main Methods:

  • Review of regulatory guidance documents from FDA, EMA, and WHO.
  • Analysis of the scientific and regulatory principles underlying comparability and biosimilarity.
  • Comparative examination of approval processes for manufacturing changes versus new biosimilar products.

Main Results:

  • Comparability assessments focus on maintaining the quality, safety, and efficacy of an existing biologic after manufacturing changes by the same manufacturer.
  • Biosimilarity evaluations assess a new biologic's high degree of similarity to a reference product.
  • Regulatory agencies globally incorporate comparability concepts into biosimilarity frameworks.

Conclusions:

  • Comparability and biosimilarity represent distinct regulatory processes with different objectives and scopes.
  • Understanding these distinctions is crucial for biopharmaceutical development and regulatory compliance.
  • Both processes aim to ensure the availability of safe and effective biologic medicines.